피부암 진단 시장 규모, 점유율, 동향 분석 보고서 : 암 유형별, 검사 유형별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Skin Cancer Diagnostics Market Growth & Trends:

The global skin cancer diagnostics market size is anticipated to reach USD 13.23 billion by 2030 and is expected to expand at a CAGR of 5.52% from 2024 to 2030, according to a new report by Grand View Research, Inc. The skin cancer diagnostics market is driven by several key factors. Rising skin cancer incidence due to increased UV exposure and aging populations is a primary driver. Advances in diagnostic technologies, such as AI-powered imaging and molecular diagnostics, enhance accuracy and early detection, further propelling market growth. Increased awareness campaigns and government initiatives promoting early screening also contribute significantly. In addition, higher healthcare expenditures and improved access to dermatological care are crucial in expanding the skin cancer diagnostics market.

Over the past decade, significant advancements have been made in approaches to melanoma detection, all aimed at reducing the growing incidence of melanoma and its mortality rate. While these advancements have been well-documented to increase early melanoma detection, there has been considerable criticism of their efficacy in improving survival rates. Traditional methods for detecting skin cancer often involve time-consuming and expensive procedures, such as PET and CT scans, as well as invasive technologies using higher frequencies.

A biosensor developed at Queen Mary University of London in April 2024 offers a noninvasive and highly efficient solution. This biosensor leverages the unique properties of THz waves, which have lower energy than X-rays and are safe for humans, to detect subtle changes in cell characteristics. In addition, scientists have developed genomic tests that provide oncologists and dermatologists with valuable information about the molecular biology of tumors, particularly in patients with aggressive skin cancers such as invasive melanomas and high-risk Squamous Cell Carcinomas (SCCs). These tests analyze genetic information from a patient's primary tumor, helping physicians better forecast the likelihood of cancer recurrence after treatment and its potential spread to other parts of the body. Furthermore, these tests offer greater patient-specific insights that are not available through traditional cancer staging, which typically uses clinical information and lab reports compared with population-based data to determine a patient's prognosis.

In the era of COVID-19, teledermatology has become increasingly popular. These emerging techniques for skin cancer diagnosis have the potential to be integrated into teledermatology in primary care settings. Furthermore, combining AI with these emerging techniques can further enhance their widespread use. More large-scale, multicenter, prospective clinical trials are needed to prevent these emerging techniques from remaining experimental equipment used in only a few special centers. This can be achieved by maintaining interest in this issue among health providers, the general population, patients, and health-related organizations in each country.

Skin Cancer Diagnostics Market Report Highlights:

• Nonmelanoma dominated the cancer type segment and is anticipated to grow at fastest growth rate over the forecast period owing to the owing to the rising incidence of Nonmelanoma Skin Cancer (NMSC) and development of novel diagnostics tools for the diagnosis of no melanoma cancer
• Skin biopsy dominated the test type segment. Skin biopsies are pivotal in skin cancer diagnostics, serving as the gold standard for definitive diagnosis. Market driving factors include the rising prevalence, advancements in biopsy techniques, and improved pathological analysis. Increased awareness and screening programs promote early detection, boosting biopsy demand
• Imaging segment is expected to grow at faster rate during the review period. Factors such as the rising incidence of skin cancer, technological advancements in imaging modalities (like dermoscopy, optical coherence tomography, and reflectance confocal microscopy), and increasing awareness about early detection contribute to market expansion. Additionally, the growing adoption of non-invasive imaging techniques, which offer improved accuracy and reduced patient discomfort, further propel market growth
• Hospitals and clinics segment dominated the end-use segment and is anticipated to grow at fastest growth rate over the forecast period. As diagnostics are being increasingly adopted, their acceptance has increased in hospitals as well. Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals are aiming to provide a wide range of services in their settings
• North America dominated the skin cancer diagnostics market owing to factors such as the presence of major key players, favorable government initiatives for the development of innovative diagnostics tools

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Cancer Type
  • 1.2.2. Test Type
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research End-use
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Cancer Type and test type outlook
  • 2.2.2. End-use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements
    • 3.2.1.2. Integration of artificial intelligence
    • 3.2.1.3. Patient preference for non-invasive diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Diagnostic Imaging
• 3.3. Skin Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

• 4.1. Global Skin Cancer Diagnostics Market: Cancer Type Dashboard
• 4.2. Global Skin Cancer Diagnostics Market: Cancer Type Movement Analysis
• 4.3. Global Skin Cancer Diagnostics Market by Cancer Type, Revenue
• 4.4. Melanoma
  • 4.4.1. Melanoma market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Non-Melanoma
  • 4.5.1. Non-Melanoma market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

• 5.1. Global Skin Cancer Diagnostics Market: Test Type Dashboard
• 5.2. Global Skin Cancer Diagnostics Market: Test Type Movement Analysis
• 5.3. Global Skin Cancer Diagnostics Market by Test Type, Revenue
• 5.4. Dermatoscopy
  • 5.4.1. Dermatoscopy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Skin Biopsy
  • 5.5.1. Skin Biopsy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Lymph node biopsy
  • 5.6.1. Lymph node biopsy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Imaging Tests
  • 5.7.1. Imaging Tests market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

• 6.1. Global Skin Cancer Diagnostics Market: End-use Dashboard
• 6.2. Global Skin Cancer Diagnostics Market: End-use Movement Analysis
• 6.3. Global Skin Cancer Diagnostics Market by End-use, Revenue
• 6.4. Hospital and Clinics
  • 6.4.1. Hospital and Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Laboratories
  • 6.5.1. Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Analysis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Castle Bioscience
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. DermTech
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. bioMerieux , Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. FOUNDATION MEDICINE, INC.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. DermaSensor, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. F . Hoffmann-La Roche Ltd
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. NeoGenomics Laboratories
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Quest Diagnostics Incorporated
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. SkylineDx
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Abbott
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives